The Discounted Cash Flow (DCF) valuation of Prometheus Biosciences Inc (RXDX) is (21.57) USD. With the latest stock price at 199.92 USD, the upside of Prometheus Biosciences Inc based on DCF is -110.8%.
Based on the latest price of 199.92 USD and our DCF valuation, Prometheus Biosciences Inc (RXDX) is a sell. selling Prometheus stocks now will result in a potential gain of 110.8%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.8% - 7.5% | 6.6% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (72.94) - (12.31) | (21.57) |
| Upside | -136.5% - -106.2% | -110.8% |